Allogene Therapeutics Inc (ALLO)

Dec 18, 2024

Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com

Dec 18, 2024

Dec 18, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 18, 2024

Dec 16, 2024

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Dec 16, 2024

Dec 16, 2024

Allogene Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Dec 16, 2024

Dec 15, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update - MarketBeat

Dec 15, 2024

Dec 13, 2024

Allogene stock hits 52-week low at $1.98 amid market challenges - Investing.com Canada

Dec 13, 2024

Dec 13, 2024

Allogene stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa

Dec 13, 2024

Dec 12, 2024

Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal phase - Investing.com

Dec 12, 2024

Dec 12, 2024

Allogene Therapeutics (ALLO) Stock Drops Amidst Biotech Sector D - GuruFocus.com

Dec 12, 2024

Dec 12, 2024

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - The Manila Times

Dec 12, 2024

Dec 12, 2024

Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - GlobeNewswire

Dec 12, 2024

Dec 12, 2024

Allogene Therapeutics Mourns Loss of Founding Board Member David Bonderman, Pioneer in CAR T-cell Innovation - StockTitan

Dec 12, 2024

Dec 11, 2024

Allogene Therapeutics, Inc. Acknowledges the Passing of Founding Board Member David Bonderman - Marketscreener.com

Dec 11, 2024

Dec 10, 2024

Insider Sell: Deborah Messemer Sells 9,136 Shares of Allogene Th - GuruFocus.com

Dec 10, 2024

Dec 10, 2024

Allogene Therapeutics: Showing Promise Despite Some Shaky Safety (NASDAQ:ALLO) - Seeking Alpha

Dec 10, 2024

Dec 10, 2024

Zacks Investment Management Purchases New Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Dec 10, 2024

Dec 09, 2024

Allogene Therapeutics (ALLO) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com

Dec 09, 2024

Dec 06, 2024

Fmr LLC Reduces Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Dec 06, 2024

Dec 03, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Large Decrease in Short Interest - MarketBeat

Dec 03, 2024

Dec 02, 2024

Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - MSN

Dec 02, 2024

Dec 02, 2024

Allogene Therapeutics Loses 23% Year To Date: How To Play The Stock? - Barchart

Dec 02, 2024

Nov 29, 2024

Vestal Point Capital LP Trims Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Nov 29, 2024

Nov 28, 2024

Allogene’s ALLO-329 shows efficacy at killing CD19- and CD70-expressing cells - BioWorld Online

Nov 28, 2024

Nov 25, 2024

Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - Yahoo Finance

Nov 25, 2024

Nov 23, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 23, 2024

Nov 22, 2024

ALLO (Allogene Therapeutics) Investments And Advances : $111.82 Mil (As of Sep. 2024) - GuruFocus.com

Nov 22, 2024

Nov 22, 2024

Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth? - Simply Wall St

Nov 22, 2024

Nov 20, 2024

Allogene stock touches 52-week low at $2 amid market challenges - Investing.com India

Nov 20, 2024

Nov 20, 2024

Allogene's Q3 Loss Narrower Than Expected, Sales Nil - MSN

Nov 20, 2024

Nov 19, 2024

ALLOAllogene Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 19, 2024

Nov 19, 2024

Allogene Therapeutics Announces Participation in December Investor Conferences - The Manila Times

Nov 19, 2024

Nov 19, 2024

Allogene Therapeutics to Present at Three Major Healthcare Conferences | ALLO Stock News - StockTitan

Nov 19, 2024

Nov 18, 2024

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence - The Manila Times

Nov 18, 2024

Nov 18, 2024

Allogene Therapeutics Presents Preclinical Data for - GlobeNewswire

Nov 18, 2024

Nov 18, 2024

Allogene's Novel Dual CAR T ALLO-329 Shows Promise in Autoimmune Disease Study | ALLO Stock News - StockTitan

Nov 18, 2024

Nov 18, 2024

Allogene Therapeutics, Inc Decides to Discontinue Enrollment in Its Phase 1 Cohort in the ALPHA2 Clinical Trial to Evaluate cemacabtagene ansegedleucel - Marketscreener.com

Nov 18, 2024

Nov 18, 2024

Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Declines By 5.8% - MarketBeat

Nov 18, 2024

Nov 15, 2024

Allogene halts enrollment in leukemia trial By Investing.com - Investing.com Australia

Nov 15, 2024

Nov 15, 2024

Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths - CGTLive™

Nov 15, 2024

Nov 14, 2024

Allogene halts enrollment in leukemia trial - Investing.com

Nov 14, 2024

Nov 14, 2024

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst Downgrade - MarketBeat

Nov 14, 2024

Nov 14, 2024

Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment - BioSpace

Nov 14, 2024

Nov 14, 2024

Piper Sandler Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00 - MarketBeat

Nov 14, 2024

Nov 14, 2024

Allogene shares target cut, rating held on trial enrollment issue By Investing.com - Investing.com UK

Nov 14, 2024

Nov 12, 2024

Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace

Nov 12, 2024

Nov 12, 2024

Allogene Therapeutics's SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com India

Nov 12, 2024